Doliver Advisors LP Acquires 110,000 Shares of ImmunityBio, Inc. $IBRX

Doliver Advisors LP boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 110.0% in the 3rd quarter, Holdings Channel reports. The firm owned 210,000 shares of the company’s stock after purchasing an additional 110,000 shares during the period. Doliver Advisors LP’s holdings in ImmunityBio were worth $1,982,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of the business. Hussman Strategic Advisors Inc. purchased a new stake in shares of ImmunityBio in the second quarter valued at about $1,287,000. SEB Asset Management AB acquired a new stake in shares of ImmunityBio during the first quarter worth about $18,770,000. Tidal Investments LLC purchased a new position in shares of ImmunityBio during the second quarter worth about $2,207,000. Winning Points Advisors LLC purchased a new position in shares of ImmunityBio during the fourth quarter worth about $1,430,000. Finally, BlackRock Inc. increased its position in ImmunityBio by 29.4% in the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after acquiring an additional 7,736,819 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

IBRX has been the subject of several analyst reports. Jefferies Financial Group raised ImmunityBio to a “strong-buy” rating in a research note on Friday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a research note on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and an average price target of $14.20.

ImmunityBio Stock Performance

ImmunityBio stock traded down $0.16 during trading hours on Thursday, reaching $9.28. 12,298,572 shares of the stock were exchanged, compared to its average volume of 20,760,051. ImmunityBio, Inc. has a 52-week low of $1.95 and a 52-week high of $12.43. The stock has a market cap of $9.84 billion, a P/E ratio of -9.57 and a beta of 0.04. The firm’s 50 day moving average is $7.92 and its 200 day moving average is $7.82.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million. Equities research analysts expect that ImmunityBio, Inc. will post -0.44 EPS for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.